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The 1st ESMO Consensus Conference on lung cancer was held in Lugano, Switzerland on 21 and 22 May 2010 with
the participation of a multidisciplinary panel of leading professionals in pathology and molecular diagnostics, medical
oncology, surgical oncology and radiation oncology. Before the conference, the expert panel prepared clinically
relevant questions concerning five areas: early and locally advanced non-small-cell lung cancer (NSCLC), first-line
metastatic NSCLC, second-/third-line NSCLC, NSCLC pathology and molecular testing, and small-cell lung cancer to
be addressed through discussion at the Consensus Conference. All relevant scientific literature for each question was
reviewed in advance. During the Consensus Conference, the panel developed recommendations for each specific
question. The consensus agreement on three of these areas: NSCLC pathology and molecular testing, the treatment
of first-line, and second-line/third-line therapy in metastatic NSCLC are reported in this article. The recommendations
detailed here are based on an expert consensus after careful review of published data. All participants have approved
this final update.
Lugano 2010: Background to the ESMO
Consensus Conference
In 2009, European Society for Medical Oncology (ESMO)
decided to update the ESMO clinical recommendations in lung
cancer through a consensus process addressing five specific
areas:
Early and locally advanced non-small-cell lung cancer (NSCLC)
NSCLC pathology and molecular testing
First-line metastatic NSCLC
Second-/third-line NSCLC
Small-cell-lung cancer (SCLC)
Five working groups were appointed, each comprised five to
nine participants with multidisciplinary involvement and led by
a chair, and with the assistance of one expert in methodological
aspects. A total of 39 experts were involved in this consensus
process (see Panel members listed in the Appendix).
The 1st ESMO Consensus Conference on Lung Cancer was
held in May 2010 in Lugano. Before the conference, each
group identified a number of clinically relevant questions
suitable for consensus discussion and provided the available
literature. At the Conference, in five parallel sessions, each
group discussed and reached agreement on the questions
previously chosen. Decisions were made using studies
published in peer review journals. The consideration of
abstracts was at the discretion of the groups. All relevant
scientific literature, as identified by the experts, was
considered. A systematic literature search was not carried
out. The recommendations from each group were then
presented to all the experts and discussed, and a general
consensus was reached. The ‘Infectious Diseases Society of
American-United States Public Health Service Grading
System’ was used (shown in Tables 1 and 2) for level of
evidence and strength of recommendation for each question
raised [1].
The consensus on three of the five areas discussed—NSCLC
pathology and molecular testing, first-line metastatic NSCLC,
and second- and third-line NSCLC—are detailed here.Table 3
provides a summary of the recommendations. The consensus
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on early and locally advanced NSCLC, and SCLC will be
reported separately. The final recommendations listed here
have been approved by all participants.
Non-small-cell lung cancer pathology
and molecular testing (Chair: R. Rosell,
participants in this working group:
F. Blackhall, F. Ciardiello, P. A. Ja¨nne,
K. Kerr, T. Mok, K. O’Byrne, M. Taron)
Lung cancer is the leading cause of cancer-related deaths, with
current chemotherapies lacking adequate specificity and
efficacy. It is possible to subdivide NSCLC patients into
genetically discrete subsets on the basis of the activating
mutations that they harbor [2]. Certain subsets of patients can
benefit from treatment with specific inhibitors; e.g. in
Caucasian patients harboring activating mutations in the
epidermal growth factor receptor (EGFR) kinase domain,
landmark outcomes of a 70% response rate, 14-month
progression-free survival (PFS) and 27-month median overall
survival (OS) have been attained with erlotinib [3]. In three
phase III trials of Asian patients with EGFR mutations, median
PFS was significantly longer in patients receiving gefitinib (9.2–
10.8 months) than in those receiving chemotherapy (5.4–6.3
months), with a significant improvement in the hazard ratios
(HRs) for progression [estimates ranging from 0.30 to 0.48; P <
0.001 [4–6] (95% confidence intervals (CI) 0.22–0.41 [6], 0.36–
0.64 [4], 0.34–0.71 [5]] (reviewed in Pao and Chmielecki [7]).
Currently, however, EGFR mutation analysis and other
molecular assessments are yet to be implemented as routine
practice [8].
To optimize and unify genetic testing in NSCLC patients, the
panel members agreed on the need to maximize tumor tissue
acquisition. Today, the majority of NSCLCs are diagnosed at an
advanced stage, and the most common diagnostic procedure is
bronchoscopy, which might not provide enough tumor tissue
for molecular assessment. Frequently, the diagnosis is based on
cytology. The role of a multidisciplinary team, including
thoracic surgeons, radiologists and pulmonologists, is essential
to obtain more tumor tissue, through the use of novel
techniques, such as transthoracic biopsy under CT guidance
and endobronchial ultrasound-guided transbronchial needle
aspiration [9, 10]. Imaging-guided needle biopsy is satisfactory
for EGFR mutation analysis. An average of 1.8 needle passes
with small (18–20 gauge) core needles yielded sufficient and
reliable samples for mutation analysis [11].
Specific subtyping of NSCLC is essential for accurate
treatment decisions; however, the World Health Organisation
lung cancer classification is applicable in full only to surgically
resected tumors [12]. A new classification of lung
adenocarcinoma has recently been published which addresses
both resected tumors and small biopsies and cytology [13].
Adenocarcinoma is the most frequent histological subtype of
lung carcinoma worldwide and is also the most histologically
variable heterogeneous form of lung cancer. Small biopsy
samples may not be representative of the whole tumor or allow
appreciation of tumor architecture. The vast majority of
pulmonary adenocarcinomas are heterogeneous tumors
showing a mixture of patterns that may well have different
biological behavior and thus potential therapeutic implications
for the patient [14]. When pathologists use the term ‘non-
small-cell carcinoma,’ a case could be made for adding
‘NOS’ (not otherwise specified). Immunohistochemistry may
be used to predict a likely specific subtype in NSCLC ‘NOS’
cases. Immunohistochemistry markers used for
subtyping should be validated with clear definitions of
a positive test. Thyroid transcription factor (TTF)-1 is positive
in 80%–85% of pulmonary adenocarcinomas. It is also
found in 20%–30% of resected large cell undifferentiated
carcinomas, in 50% of large cell neuroendocrine carcinomas,
and in some adenocarcinomas that may metastasize to the lung
[14]. p63 is expressed in all squamous cell carcinomas, but also
in around one-third of adenocarcinomas (reviewed by Kerr
[14]). Between 80% and 90% of surgically resected
adenocarcinomas show more than one of the common patterns
(acinar, papillary, bronchioloalveolar or solid). Consequently,
there are a number of issues to consider when reporting tumor
type [13].
1. Is there sufficient evidence to support the
routine application of EGFR somatic mutation
assessment?
EGFR-mutant NSCLC was first recognized in 2004 as
a distinct clinically relevant molecular subset of lung cancer
Table 1. Level of evidence [1]
I Evidence from at least one large randomized control trial of
good methodological quality (low potential for bias) or
meta-analyses of well-conducted randomized trials
without heterogeneity
II Small randomized trials or large randomized trials with
a suspicion of bias (lower methodological quality) or
meta-analyses of such trials or of trials demonstrated
heterogeneity
III Prospective cohort studies
IV Retrospective cohort studies or case-control studies
V Studies without control group, case reports, experts
opinions
Table 2. Strength of recommendation [1]
A Strong evidence for efficacy with a substantial clinical
benefit, strongly recommended
B Strong or moderate evidence for efficacy but with a limited
clinical benefit, generally recommended
C Insufficient evidence for efficacy or benefit does not
outweigh the risk or the disadvantages (adverse events,
costs, . ), optional
D Moderate evidence against efficacy or for adverse outcome,
generally not recommended
E Strong evidence against efficacy or for adverse outcome,
never recommended
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Table 3. Summary of recommendations
NSCLC pathology and molecular testing
Recommendation 1 –EGFR somatic mutation testing should be carried out to identify patients eligible for first-line
treatment with EGFR TKIs
–Never/former light smokers (<15 packs per year) or patients withnonsquamous histology should
be tested for EGFR mutation status regardless of PS
–Patients harboring sensitizing EGFR mutations should be treated with EGFR TKIs regardless of the
genotype of the sensitizing mutation (del 19 versus L858R in exon 21)
–IHC and FISH for EGFR are not recommended for routine clinical use
–The concomitant presence of T790M resistance mutation shouldnot preclude the use of EGFR TKIs
in the first-line setting
–DNA derived from tumor biopsy is the optimal source for EGFR somatic mutation testing; repeat
biopsy may be indicated to gain sufficient material to test. There is no evidence to mandate testing
for an EGFR somatic mutation outside the first-line setting
Recommendation 2 –A pathologist should be involved in sample preparation and result interpretation of EGFR mutation
status. Micro- or macrodissection of samples can maximize tumor cell content before DNA
extraction. The report should include comment on source, quantity and quality of tested sample
and should follow guidance on genetic test reporting such as that provided by the Swiss Society of
Medical Genetics (http://www.sgmg.chand) and the Human Genome Variation Society for
nomenclature guidelines (http://www.hgvs.org)
Recommendation 3 –Somatic mutation tests that are required for clinical decision making should be carried out in
laboratories that are compliant with country-specific standards for clinical diagnostic testing (UK,
Clinical Pathology Accredited Laboratories; USA, CLIA Laboratories). The laboratory should have
accreditation to conduct the test and should participate in internal and external quality assurance
to maintain accreditation (EMQN, UKNEQAS)
Recommendation 4 –Routine testing for EML4-ALK is not currently recommended outside of clinical trials. However,
emerging data for ALK inhibition are promising and may lead to a clinical indication for routine
testing
Recommendation 5 –Routine testing for KRAS, BRAF, ERBB2, PIK3CA somatic gene mutations is not currently
recommended outside of clinical trials
Recommendation 6 –Routine testing for mRNA levels of ERCC1, RRM1, TS and BRCA1 is not currently recommended
outside of clinical trials
First-line metastatic NSCLC
Recommendation 1 –First-line chemotherapy should be offered to patients with metastatic NSCLC and PS 0–2
Recommendation 2 –The administration of first-line chemotherapy should be offered at diagnosis to asymptomatic
patients with metastatic NSCLC
Recommendation 3 –Platinum-based chemotherapy is preferred to non-platinum-based chemotherapy in eligible patients
with metastatic NSCLC
Recommendation 4 –Cisplatin should be used in fit patients with PS 0–1 who have adequate organ function
Recommendation 5 –In PS 2 patients either single-agent chemotherapy or platinum-based combinations are valid
options
Recommendation 6 –Platinum-based chemotherapy is preferred in fit elderly patients with PS 0–1 and adequate organ
function. Single-agent third-generation drugs are preferred in unfit elderly patients
Recommendation 7 – There is no standard platinum-based doublet for metastatic NSCLC. In a preplanned subgroup
analysis cisplatin/pemetrexed was shown to be superior in nonsquamous histology and inferior in
squamous histology as compared with cisplatin/gemcitabine, but without comparison with other
doublets
Recommendation 8 – Four to six chemotherapy cycles should be given
Recommendation 9 – ‘Switch maintenance’ treatment with erlotinib or pemetrexed following completion of first-line
chemotherapy is an option. Decision factors for the use of ‘switch maintenance’ include histology,
type and response to first-line chemotherapy, residual toxicity, patient‘s symptoms and preference.
Any patient whose tumor harbors an EGFR activating mutation should receive an EGFR TKI as
maintenance, if not yet received as first line
Recommendation 10 – Bevacizumab combined with platinum-based chemotherapy is a treatment option in eligible
patients with nonsquamous NSCLC, in particular when carboplatin/paclitaxel combination is the
chemotherapy backbone
Recommendation 11 – Cetuximab added to platinum-based chemotherapy can be considered as a treatment option for
patients with EGFR IHC-positive metastatic NSCLC, in particular when cisplatin/vinorelbine is
the chemotherapy backbone
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[15–17]. The disease has been the subject of intensive
research at the basic and clinical levels, becoming a paradigm
for how to understand and treat oncogene-driven carcinomas
[7]. In 2009, trials in EGFR-mutant lung cancer with EGFR
tyrosine kinase inhibitors (TKIs) reported the longest survival
rates currently seen for metastatic NSCLC [3, 4]. Although
patients with EGFR-mutant tumors have increased
sensitivity to an EGFR TKI, primary and acquired resistance to
these agents remains a major clinical problem. The T790M
‘acquired resistance mutation’ was observed in 45 of 129
patients (35%) [18]. Three different studies showed that
patients with EGFR mutations had shorter PFS when the tumor
had a very small amount of T790M before EGFR TKI therapy
[18–20].
Recommendation 1.1: EGFR somatic mutation testing should
be carried out to identify patients eligible for first-line
treatment with EGFR TKIs.
Strength of recommendation: A
Level of evidence: I
Recommendation 1.2: never/former light smokers (< 15 packs
per year) or patients with nonsquamous histology should be
tested regardless of performance status (PS).
Strength of recommendation: B
Level of evidence: II
Recommendation 1.3: patients harboring sensitizing EGFR
mutations should be treated with EGFR TKIs regardless of the
genotype of the sensitizing mutation (deletion in exon 19 [del
19] versus L858R in exon 21) [3–6, 21].
Strength of recommendation: A
Level of evidence: II
Recommendation 1.4: immunohistochemistry and FISH for
EGFR are not recommended for routine clinical use [4, 21].
Strength of recommendation: A
Level of evidence: II
Other recommendations: the concomitant presence of
T790M resistance mutation should not preclude the use of
EGFR TKIs in the first-line setting. DNA derived from
tumor biopsy is the optimal source for EGFR somatic
mutation testing; repeat biopsy may be indicated to gain
sufficient material to test. There is no evidence to mandate
testing for an EGFR somatic mutation outside the first-line
setting.
2. Guidance on tissue handling and reporting for
EGFR somatic mutation testing
Handling of tumor specimens has yet to be standardized. In
a previous workshop on EGFR mutation testing [8], the
participants reached an agreement that 10% neutral-buffered
formalin is the optimum fixative, whereas Bouin’s fluid should
not be used and other fixatives have yet to be validated against
formalin. The fixation time should be optimal for tissue
specimen and not prolonged, yet sufficient to permit diagnosis.
Sections cut from the formalin-fixed paraffin-embedded tissue
block are the standard resource used for DNA extraction.
Between one and six sections of 5- to 10-lm thickness should be
used. Laboratories that use laser capture microdissection will
require thinner sections. Tissue fixation and processing have the
potential to denature DNA, especially when using automated
processes [8].
Recommendation 2: a pathologist should be involved in sample
preparation and result interpretation. Micro- or macrodissection
of samples can maximize tumor cell content before DNA
extraction. The report should include comment on source,
quantity and quality of tested sample and should follow guidance
on genetic test reporting such as that provided by the Swiss
Society of Medical Genetics (http://www.sgmg.chand) and the
Table 3. (Continued)
Recommendation 12 – An EGFR TKI is the preferred first-line treatment in patients whose tumor harbors an activating
EGFR mutation
Recommendation 13 – Local treatment to brain followed by systemic therapy is the standard approach for patients with
brain metastases at diagnosis. Local treatment may be delayed in asymptomatic patients
Second-/third-line NSCLC
Recommendation 1 – Second- or third-line therapy should be offered to patients with good PS who present with signs of
disease progression (radiological and/or clinical) after first or second-line therapy
Recommendation 2 – In second-line, chemotherapy or an EGFR TKI can be offered to patients. In third-line, an EGFR
TKI may be considered when patients have not received EGFR TKIs previously. Patients in good
general condition in third or subsequent lines should be entered in clinical studies
Recommendation 3 – Patients with symptomatic brain metastases may be considered for treatment with an EGFR TKI
Recommendation 4 – Age alone is not considered to be an exclusion criterion for second or third-line therapy
Recommendation 5 – Different drugs have been registered for treating patients who progress during first-line therapy
Recommendation 6 – For non-squamous tumors, data support the use of second-line pemetrexed or EGFR TKIs
– For squamous tumors, data support the use of second-line docetaxel or EGFR TKIs
Recommendation 7 – In the presence of EGFR sensitizing mutations, the use of an EGFR TKI is recommended if not
received previously
– Second or third-line therapy with an EGFR TKI might be considered even in patients with PS 3-4
harboring an activating EGFR mutation
EGFR, epidermal growth factor receptor; IHC, immunohistochemistry; NSCLC, non-small-cell lung cancer; PS, performance status; TKIs, tyrosine kinase
inhibitors.
special article Annals of Oncology
1510 | Felip et al. Volume 22 | No. 7 | July 2011
Human Genome Variation Society for nomenclature guidelines
(http://www.hgvs.org).
Strength of recommendation: A
Level of evidence: I
3. The relevance of participation in quality
assurance programs for genetic testing
Molecular genetic techniques have been included in many areas of
clinical practice. To maintain confidence in this technology, it is
essential that the steps taken to ensure quality are clear and
transparent to participants and public. External quality assessment
schemes provide a mean of monitoring compliance with best
practice procedures [22].
Recommendation 3: somatic mutation tests that are required
for clinical decision making should be carried out in
laboratories that are compliant with country-specific standards
for clinical diagnostic testing (UK, Clinical Pathology
Accredited Laboratories; USA, CLIA Laboratories). The
laboratory should have accreditation to conduct the test and
should participate in internal and external quality assurance to
maintain accreditation (The European Molecular Genetics
Quality Network, United Kingdom National External Quality
Assessment Service).
Strength of recommendation: A
Level of evidence: V
4. Guidelines for testing EML4-ALK for treatment
selection
Oncogenic fusion genes consisting of EML4 and anaplastic
lymphoma kinase (ALK) are present in a subgroup of NSCLC,
representing 2%–7% of tumors. Echinoderm microtubule-
associated protein-like 4 (EML4)-ALK is more prevalent in
patients who have never smoked or who have a history of light
smoking and in patients with adenocarcinomas, particularly
those with the rare signet-ring appearance. Among never-
smokers and light smokers without EGFR mutations, the
frequency of EML4-ALK rearrangement was 33% [23]. In
a more recent study, the frequency reached 44.8% [24]. ALK-
rearranged tumors (82%) showed, at least focally, tumor cells
with abundant intracellular mucin and small marginalized
nuclei. This distinct cytological characteristic, unusual for lung
carcinoma, is reminiscent of the signet-ring cells more
commonly seen in gastric, colon and breast adenocarcinomas
[25]. However, ALK rearrangements are also found in other
subtypes of lung adenocarcinomas. Crizotinib is an oral ATP-
competitive selective inhibitor of the ALK and MET tyrosine
kinases. In a recent phase II trial, the response rate to crizotinib
was 57% in patients with FISH-positive EML4-ALK
rearrangements, and 77% of patients were continuing to receive
crizotinib at the time of data cut-off. The estimated probability
of 6 months PFS was 72%, with no median for the study
reached [26].
Recommendation 4: routine testing for EML4-ALK is not
currently recommended outside of clinical trials. However,
emerging data for ALK inhibition are promising and may lead
to a clinical indication for routine testing.
Strength of recommendation: A
Level of evidence: V
5. Guidelines for testing other somatic gene
mutations for treatment selection: KRAS, BRAF,
ERBB2, PIK3CA
PIK3CA mutations were identified in 4.7% of NSCLC cell lines
and in 1.6% of tumors of all major histological types among
691 resected NSCLC patients. Mutational status of PIK3CA was
not mutually exclusive to EGFR or KRAS mutations [27]. In
addition, ERBB2 mutations were present in 1.6% of NSCLC
patients. All ERBB2 mutations were in-frame insertions in exon
20 that target the identical corresponding region as EGFR
insertions. ERBB2 mutations were significantly more frequent
in never-smokers and those with adenocarcinomas. EGFR,
ERBB2 and KRAS mutations were mutually exclusive [28, 29].
Mutations in BRAF are observed at low frequency (2% of
NSCLCs) [30].
Recommendation 5: routine testing for KRAS, BRAF, ERBB2,
PIK3CA somatic gene mutations is not currently recommended
outside of clinical trials.
Strength of recommendation: A
Level of evidence: V
6. What is the role of customizing chemotherapy
based on mRNA levels of ERCC1, RRM1, TS and
BRCA1?
A trial of customized treatment based on ERCC1 mRNA levels
did not demonstrate a benefit for this approach [31].
Retrospective assessment of RRM1 and TS in stage IV NSCLC
patients treated with cisplatin/gemcitabine indicated a potential
role for these biomarkers [32, 33]. Based on the differential
modulating effect of BRCA1 observed in the breast cancer cell
line with mutant BRCA1 HCC1937 [34], BRCA1 mRNA levels
have been examined retrospectively in NSCLC patients to
predict outcome to cisplatin-based chemotherapy [35, 36].
A prospective phase II study of customized chemotherapy
based on BRCA1 levels showed no conclusive evidence for
improved outcome in stage IV NSCLC patients. However, an
exploratory analysis of RAP80 mRNA levels showed substantial
benefit in patients with low levels of both RAP80 and BRCA1
treated with cisplatin/gemcitabine [37]. Based on these
findings, two phase III randomized trials of customized
chemotherapy based on RAP80 and BRCA1 levels are being
carried out.
Recommendation 6: routine testing for mRNA levels of
ERCC1, RRM1, TS and BRCA1 is not currently recommended
outside of clinical trials.
Strength of recommendation: A
Level of evidence: V
First-line metastatic non-small-cell
lung cancer (Chair: C. Gridelli,
participants in this working group:
B. Besse, D. Gandara, F. de Marinis,
J.P. van Meerbeeck, L. Paz-Ares,
R. Pirker, M. Reck, E.F. Smit)
Lung cancer is the most common cancer in the world and the
leading cause of cancer-related deaths worldwide with 1.35
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million new diagnoses and 1.18 million deaths worldwide in
2002 [38]. Every year, in Europe, >200 000 new cancer cases are
diagnosed, accounting for 20% of all cancer deaths [39].
NSCLC, including adenocarcinoma, squamous carcinoma and
large-cell carcinoma, make up >80%–85% of all lung cancer
types with 70% of patients presenting with advanced disease
at diagnosis. The majority of patients diagnosed with NSCLC
are unsuitable for curative treatment due to advanced disease,
thus systemic therapy is the standard approach with palliation,
patients’ quality of life (QOL) and prolongation of life being
the goal of therapy.
1. Should first-line chemotherapy be offered to all
patients with metastatic NSCLC?
First-line chemotherapy is shown to be effective in metastatic
NSCLC patients with PS 0-2 in trials comparing platinum-
based chemotherapy or even single-agent chemotherapy with
best supportive care (BSC) [40].
Recommendation 1: first-line chemotherapy should be offered
to patients with metastatic NSCLC and PS 0–2.
Strength of recommendation: A
Level of evidence: I
2. Should we start first-line chemotherapy in
asymptomatic stable patients with metastatic
NSCLC immediately or at onset/progression of
symptoms?
The survival benefit achieved by palliative chemotherapy in
asymptomatic patients with metastatic NSCLC is of the same
magnitude as in symptomatic ones [40]. Furthermore, QOL
either was not worse or improved for those patients receiving
chemotherapy in eight clinical trials, four with platinum-based
and four with single-agent third-generation drugs [41].
Although not less effective, delaying palliative chemotherapy
until symptomatic progression may result in shorter time to
progression, worsening of QOL and less drug exposure, all of
which are potentially detrimental to outcome [42].
Recommendation 2: the administration of first-line
chemotherapy should be offered at diagnosis to asymptomatic
patients with metastatic NSCLC.
Strength of recommendation: C
Level of evidence: III
3. Should we use platinum or non-platinum-based
chemotherapy?
Non-platinum-based chemotherapy regimens have been
proposed as alternatives to platinum-based doublets for the
treatment of metastatic NSCLC. Two meta-analyses have
addressed this issue [43, 44]. D’Addario et al. [43] analyzed the
outcomes of 37 randomized phase II and III studies including
7633 patients and 42 pairwise comparisons (platinum versus
nonplatinum). When analyzed for response rate, platinum-
containing regimens yielded a 62% increase in the odds for
response (95% CI for odds ratio [OR], 1.46–1.8, P < 0.0001).
There was a 5% increase in 1-year survival rate (OR 1.21; 95%
CI 1.09–1.35, P = 0.0003) with platinum-based regimens but
nonstatistically significant differences were found when only
regimens including third-generation drugs were included.
Platinum-based regimens are associated with higher frequencies
of nausea and vomiting, and renal and hematological toxic
effects, although none led to increases in febrile neutropenia or
toxic death rate. Pujol et al. analyzed the outcomes of 11
randomized phase III studies including 4602 patients that had
1-year survival as one of the endpoints [44]. The absolute
survival benefit for patients treated with platinum-based
chemotherapy was 3% at 1 year, corresponding to a reduction
in the risk of death within the first year with an OR of 0.88
(95% CI 0.78–0.99, P = 0.044). Again, there was a slight
increase in the incidence of gastrointestinal toxicity but no
increase in the rate of toxic deaths. Both meta-analyses
concluded platinum-based chemotherapy to be superior to
non-platinum-based chemotherapy in metastatic NSCLC.
Recommendation 3: platinum-based chemotherapy is
preferred to non-platinum-based chemotherapy in eligible
patients with metastatic NSCLC.
Strength of recommendation: A
Level of evidence: I
4. Should we use cisplatin or carboplatin-based
chemotherapy?
Concerns about the toxic effects associated with cisplatin-based
chemotherapy and the availability of platinum analogs with
fewer side effects have led to a number of randomized trials in
metastatic NSCLC patients. Two meta-analyses have been
published that address this issue [45, 46]. Hotta et al. [45]
analyzed eight trials and reported a higher response rate for
cisplatin compared with carboplatin treatment with no survival
difference. Subgroup analyses revealed that patients treated
with a third-generation compound in conjunction with
carboplatin had a shorter survival than those receiving cisplatin
plus the same agents (HR 1.106, 95% CI 1.005–1.218; P =
0.039). This survival advantage was obtained at the cost of
a higher but not statistically significant difference in terms of
lethal toxic effects. In a more recent meta-analysis using
individual patient data, Ardizzoni et al. [46] observed
a significant increase in response for the cisplatin-treated
patients, with no significant survival difference. In
a prespecified analysis, the authors found an interaction
between histology and the use of third-generation agents;
patients with nonsquamous tumor fared better when treated
with cisplatin-based chemotherapy. Furthermore, once again,
patients treated with third-generation compounds in
conjunction with cisplatin had a longer survival as compared
with those treated with carboplatin plus the same agent. The
results were similar to the Hotta et al. [45] analysis with regard
to toxic effects.
Recommendation 4: cisplatin should be used in fit patients
with PS 0-1 who have adequate organ function.
Strength of recommendation: B
Level of evidence: I
5. Which chemotherapy should we use for PS 2
patients?
On the basis of current evidence, chemotherapy appears
justified in patients with advanced NSCLC and a PS of 2.
Subgroup analyses from several randomized trials suggest
that several new-generation cytotoxic drugs are superior to
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BSC alone in this category of patients [47]. Therefore, single-
agent chemotherapy with these drugs (e.g. gemcitabine,
vinorelbine, and taxanes) represents an historical option for
palliative treatment of these patients. No data justify the use of
platinum-free or high-dose (>100 mg/m2) cisplatin-based
combination chemotherapy instead of single-agent treatment
in this group of patients [47]. Taking into account the
superiority shown by the carboplatin/paclitaxel combination
compared with paclitaxel alone in a subgroup analysis of PS 2
patients [48], and the efficacy and the tolerability showed by
carboplatin-based doublets [49] in one randomized trial,
platinum-based combinations may also be considered as an
option for these patients.
Recommendation 5: in PS 2 patients either single-agent
chemotherapy or platinum-based combinations are valid
options.
Strength of recommendation: B
Level of evidence: I
6. Which chemotherapy for elderly patients?
More than 50% of NSCLCs are diagnosed in patients aged >65
years with 30% being in patients >70 years. Two main
randomized phase III trials showed single-agent chemotherapy
with third-generation agents as the standard of care for
first-line therapy for clinically unselected elderly advanced
NSCLC patients [41, 50]. However, retrospective analyses from
large phase III randomized trials showed similar efficacy and
tolerability when elderly and adult patients were compared
[51]. This issue has recently been addressed in a prospective
randomized trial comparing monthly carboplatin plus weekly
paclitaxel versus single-agent vinorelbine or gemcitabine,
reporting a survival advantage for combination therapy but
with increased toxicity (neutropenia and febrile neutropenia)
[52]. Platinum-based chemotherapy may therefore be the
preferred option for elderly patients with PS 0–1 and adequate
organ function, while single-agent is recommended for unfit
patients.
Recommendation 6: platinum-based chemotherapy is
preferred in fit elderly patients with PS 0–1 and adequate organ
function. Single-agent third-generation drugs are preferred in
unfit elderly patients.
Strength of recommendation: B
Level of evidence: I
7. Is there a single standard platinum-based
doublet chemotherapy option for metastatic
NSCLC?
Randomized studies that have compared platinum-based
doublets including third-generation drugs (vinorelbine,
gemcitabine, taxanes) among themselves [53–55] did
not show any differences in survival and gave no evidence for
a single ‘standard’ doublet for the treatment of metastatic
NSCLC. The observation that docetaxel/cisplatin was
superior to vinorelbine/cisplatin in a randomized study [54]
has not had other confirmations. A phase III randomized trial
comparing cisplatin/pemetrexed versus cisplatin/gemcitabine
showed no difference in outcome between the two
combinations with a lower hematological toxicity profile for the
pemetrexed-based regimen [56]. A preplanned subgroup
analysis showed a survival advantage for cisplatin/pemetrexed
as compared with cisplatin/gemcitabine in nonsquamous
histology (11.8 versus 10.4 months, respectively; HR 0.81,
95% CI 0.70–0.94; P = 0.005), while a survival advantage for the
gemcitabine-based combination was observed in
squamous histology. No prospective confirmative trials
have been carried out. To date no comparative data of
cisplatin/pemetrexed versus other platinum-based doublets
are available.
Recommendation 7: no, there is no standard platinum-based
doublet for metastatic NSCLC. In a preplanned subgroup analysis
cisplatin/pemetrexed was shown to be superior in nonsquamous
histology and inferior in squamous histology as compared with
cisplatin/gemcitabine, but without comparison with other
doublets.
Strength of recommendation: A
Level of evidence: I
8. How many cycles of chemotherapy?
Two randomized phase III trials compared three versus six cycles
of chemotherapy with cisplatin/vinblastine/mitomycin, and
carboplatin/ vinorelbine, respectively [57, 58]. Both trials reported
no significant differences in any of the outcomes, except increased
toxicity for the more prolonged treatment. However these two
trials were underpowered and considered inconclusive.
Recommendation 8: four cycles of chemotherapy appear
sufficient in most NSCLC patients but six cycles may be
considered depending on response and toxicity.
Strength of recommendation: B
Level of evidence: II
9. Should we recommend maintenance treatment
and if yes to which patients?
Maintenance therapy is the continued administration of
therapy after a defined number of induction therapy cycles
once disease stabilization or maximum tumor response has
been achieved, and may be continued until either disease
progression or unacceptable toxicity. It consists both of drugs
included in the induction regimen or other non-cross-
resistant agents defining the ‘early second line’ or ‘switch
maintenance’ [59]. Two main phase III randomized trials
addressed the issue of ‘switch maintenance’ therapy with
pemetrexed or erlotinib after four cycles of platinum-based
chemotherapy [21, 60]. Both trials reported PFS and OS
advantages for maintenance therapy (pemetrexed or erlotinib)
versus placebo. In the pemetrexed study, OS for nonsquamous
histology was 15.5 versus 10.3 months in the pemetrexed and
the placebo arms, respectively (HR 0.70, 95% CI 0.56–0.88;
P = 0.002) [60]. PFS was also significantly improved with
maintenance pemetrexed in this histological subgroup (4.4
versus 1.8 months, respectively; HR 0.47, 95% CI 0.37–0.60;
P < 0.0001). In the erlotinib versus placebo study, PFS was
significantly longer with erlotinib (HR 0.71, 95% CI 0.62–
0.82; P < 0.0001) and also a survival advantage was observed
(median survival of 12 versus 11 months, HR 0.81, 95%
CI 0.70–0.95; P = 0.0088) [21]. Subgroup analyses showed
a greater benefit for erlotinib in patients with stable disease
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after induction chemotherapy and in patients with tumor
harboring EGFR mutation. Unfortunately, neither trial
addressed the question of ‘early second line’ (or ‘switch
maintenance’) versus common second-line treatment started
at disease progression. However, factors to consider for
treatment in clinical practice include histology, type and
response to first-line chemotherapy, residual toxicity, patient’s
symptoms and preference. Any patient with mutated EGFR
tumor should receive an EGFR TKI as maintenance, if not
received as first line.
Although randomized trials investigating the prolonged use
of one of the components of the induction regimen have
consistently shown an improvement of PFS, this does not
translate in improved OS.
Recommendation 9: ‘switch maintenance’ treatment with
erlotinib or pemetrexed following completion of first-line
chemotherapy is an option. Decision factors for the use of
‘switch maintenance’ include histology, type and response to
first-line chemotherapy, residual toxicity, patient‘s symptoms
and preference. Any patient whose tumor harbors an activating
EGFR mutation should receive an EGFR TKI as maintenance, if
not yet received as first line.
Strength of recommendation: B
Level of evidence: I
10. The use of bevacizumab is restricted to
selected patients with nonsquamous histology.
With which chemotherapy should it be combined?
Two phase III randomized trials showed superiority of
platinum-based chemotherapy plus bevacizumab as
compared with chemotherapy alone [61, 62]. Both studies
were conducted in chemotherapy-naive patients with stage
IIIB/IV nonsquamous NSCLC and PS of 0-1; due to safety
concerns, patients with brain metastases, gross hemoptysis
and those receiving therapeutic anticoagulation were
excluded. In the ECOG 4599 study, bevacizumab/carboplatin/
paclitaxel versus carboplatin/paclitaxel was evaluated [61].
The OS was significantly longer in patients receiving
combined treatment than in those receiving chemotherapy
alone (median survival: 12.3 versus 10.3 months; HR 0.79,
95% CI 0.67–0.92; P = 0.003). Median PFS times in the two
groups were 6.2 and 4.5 months, respectively (HR 0.66, 95%
CI 0.57–0.77; P < 0.001), with corresponding response rates of
35% and 15% (P < 0.001) [61]. The second phase III trial,
enrolling outside the United States, has evaluated the
combination of bevacizumab (15 mg/kg or 7.5 mg/kg every
3 weeks until disease progression) with gemcitabine /cisplatin
versus gemcitabine/cisplatin plus placebo [62]. The
primary end point was PFS. This trial was not powered to
compare the two doses of bevacizumab directly. The PFS
was significantly longer in patients receiving
chemotherapy plus bevacizumab than in those receiving
chemotherapy plus placebo [placebo arm: median PFS
6.1 months; 7.5 mg/kg bevacizumab arm: median
PFS 6.7 months (HR 0.75, 95% CI 0.64–0.87; P = 0.0003);
15 mg/kg bevacizumab arm: median PFS 6.5 months
(HR 0.85, 95% CI 0.73–1.00; P = 0.045)]. In this trial, there
was no survival benefit for patients receiving bevacizumab
versus placebo.
Recommendation 10: bevacizumab combined with platinum-
based chemotherapy is a treatment option in eligible patients
with nonsquamous NSCLC, in particular when carboplatin/
paclitaxel combination is the chemotherapy backbone.
Strength of recommendation: B
Level of evidence: I
11. Is there a role for cetuximab?
Cetuximab has been studied in combination with different
chemotherapy regimens in patients with advanced NSCLC. In
the phase III FLEX trial, cetuximab added to cisplatin/
vinorelbine increased survival compared with the same
chemotherapy alone in patients with advanced NSCLC
expressing EGFR by immunohistochemistry (median survival
11.3 versus 10.1 months, HR 0.87, 95% CI 0.76–0.99; P = 0.04)
[63]. In the second phase III trial in patients not selected
according to EGFR expression, cetuximab added to
carboplatin/paclitaxel or docetaxel failed to improve PFS, the
primary end point [64]. A meta-analysis of 2018 patients from
two randomized phase II trials and the two phase III trials
confirmed the efficacy of cetuximab when added to
chemotherapy [65]. The benefit of cetuximab was seen
irrespective of either histological subtype or type of platinum-
based chemotherapy. The main cetuximab-related adverse
event is an acne-like rash that has been shown to be associated
with prolonged survival [66].
At present cetuximab is not approved by regulatory agencies
for the treatment of NSCLC.
Recommendation 11: cetuximab added to platinum-based
chemotherapy can be considered as a treatment option for
patients with EGFR immunohistochemistry positive metastatic
NSCLC, in particular when cisplatin/vinorelbine is the
chemotherapy backbone.
Strength of recommendation: B
Level of evidence: I
12. What is the preferred first-line treatment in
patients with a tumor harboring an activating EGFR
mutation?
In 2004, two research groups discovered the existence of
certain tumor-associated activating mutations in the tyrosine-
kinase domain of the EGFR gene of NSCLC [15, 16]. These
gain-of-function mutations enhance EGFR activation, are
transforming and markedly increase sensitivity to EGFR TKIs.
The most common oncogenic mutations are deletions in exon
19 (45%–50% of all somatic EGFR mutations) and a point
mutation (L858R) in exon 21 (35%–45% of mutations) [3, 4].
The presence of these mutations has been associated with
specific clinical and epidemiological characteristics (females,
Asians, nonsmokers, and adenocarcinoma histology).
Furthermore, patients with tumors harboring these mutations
had an extraordinary outcome with EGFR TKIs, including
response rates >60% and median survival exceeding 24
months [3, 4].
In a phase III open-label study, previously untreated
patients in East Asia who had advanced pulmonary
adenocarcinoma and who were never-smokers or former
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light smokers were randomized to receive gefitinib (609
patients) or carboplatin/paclitaxel (608 patients) [4]. In the
subgroup of 261 patients who had EGFR-mutation-positive
tumors, PFS was significantly longer among those who
received gefitinib than among those who received
carboplatin/paclitaxel (HR 0.48; 95% CI 0.36–0.64;
P < 0.001), whereas in the subgroup of 176 patients whose
tumors were negative for the mutation, PFS was significantly
longer among those who received carboplatin/paclitaxel (HR
2.85; 95% CI 2.05–3.98; P < 0.001). Two phase III trials in
East Asian patients selected because of having a tumor
harboring EGFR mutation compared gefitinib with
platinum-based chemotherapy and gave consistent results in
terms of PFS [5, 6]. Other randomized phase III trials have
been designed to test the efficacy of erlotinib as first-line
treatment of patients with EGFR-mutation-positive tumors.
The OPTIMAL phase III trial, conducted in China, showed
erlotinib significantly superior to carboplatin/gemcitabine
chemotherapy in terms of PFS, which was the primary end
point: median PFS was 4.6 months with chemotherapy
compared with 13.1 months with erlotinib (HR 0.16, 95%
CI 0.10–0.26; P < 0.0001) [67]. Phase III randomized trials
comparing erlotinib or afatinib with chemotherapy
in untreated patients harboring EGFR mutations are
ongoing.
Currently, gefitinib is registered for this indication within the
EU. Erlotinib, another EGFR TKI, is not yet approved for this
indication by regulatory agencies.
Recommendation 12: an EGFR TKI is the preferred first-line
treatment in patients whose tumor harbors an activating EGFR
mutation.
Strength of recommendation: A
Level of evidence: I
13. What is the optimal sequence of local and
systemic treatment of patients with brain
metastases at diagnosis?
Approximately 18% of all brain metastases are caused by
lung cancer [68]. Treatment options are usually based on
local approaches [surgery, radiosurgery or whole-brain
radiation therapy (WBRT)] depending on the number and
site of brain metastases. Systemic treatment has been
thought to be inadequate due to the blood–brain barrier.
However, previously untreated patients with brain
metastases have been shown to have response rates with
chemotherapy that are comparable with those found in
extracranial disease [69]. In a randomized phase III trial,
OS was not modified by delaying WBRT in patients with brain
metastases at diagnosis who received front-line cisplatin-based
chemotherapy [69]. However, the control of neurological
symptoms influences QOL and should drive the therapeutic
strategy.
Recommendation 13: local treatment to brain followed by
systemic therapy is the standard approach for patients with
brain metastases at diagnosis. Local treatment may be delayed
in asymptomatic patients.
Strength of recommendation: B
Level of evidence: II
Second- and third-line therapy in non-
small-cell lung cancer (Chair: P. Baas,
participants in this working group:
F. Cappuzzo, R. Dziadziuszko, G. Goss,
S.M. Lee, C. Manegold, A. Vergnenegre)
Treatment decisions in second and third-line therapy should
take into account a number of factors: histology, age, PS,
comorbidities, previous therapy, molecular features, potential
side effects, ultimate goal of the treatment and patients’
preferences. The choice of therapy should be made preferably at
a tumor board conference or during a multidisciplinary
discussion.
Second-line therapy can be defined as any treatment
following first-line therapy for metastatic NSCLC,
irrespective of any maintenance or adjuvant therapy. The goal
of second- or third-line treatment is prolongation of life and
symptom control. Patients who are candidates for this
indication should be selected on the basis of the time to
progression, PS, and the kind of first-line treatment previously
delivered. Age alone is not considered to be an exclusion
criterion for treatment and those presenting with
symptomatic brain metastases might be considered for EGFR
TKI treatment. There is no convincing evidence that patients
with PS > 2 will benefit from chemotherapy, but selected
patients with PS 4 and sensitizing EGFR mutations might
benefit from the administration of EGFR TKIs. The
registered options for second-line treatment are presented
in Table 4 [70–73].
Patients who progress after second-line chemotherapy may
be candidates for further treatment. Currently, only erlotinib is
registered for this indication. This treatment is only
indicated for patients who have not yet received EGFR TKIs
regardless of the PS. There are no randomized studies
addressing how long second-line treatment should continue. In
both the erlotinib versus placebo and the pemetrexed versus
docetaxel studies in second-line therapy was given until disease
progression. It is generally accepted that in the case of response
and acceptable toxicity, a minimum of four cycles is advisable.
Continuation of treatment can be considered in selected cases.
Continuing treatment beyond disease progression is not
recommended.
1. Which patients should receive second or third-
line therapy?
Patients who show signs of radiological or clinical progression
after first- or second-line therapy should be considered for
second-/third-line therapy. Various studies have shown
Table 4. Second-line treatment
Drug registered for NSCLC Line of treatment
Erlotinib [70] Second or third line
Pemetrexed [71] Second line
Docetaxel [72] Second line
NSCLC, non-small-cell lung cancer.
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response rates 10%, improvement in disease related
symptoms and increased time to progression associated with
the use of second-/third-line therapy. However, there is
a prerequisite that these patients are in a relatively good
general condition (PS 0–2) [71,72]. Second-line
combination regimens failed to show any benefit over
single-agent treatment.
Recommendation 1: second or third-line therapy should be
offered to patients with good PS who present with signs of
disease progression (radiological and/or clinical) after first or
second-line therapy.
Strength of recommendation: A
Level of evidence: I
2. What kind of treatment should be offered in
second line? What kind of treatment should be
offered in third line?
There are a number of agents registered for use in second-line
therapy (see Table 4) [70–72]. The choice of therapy should take
into consideration what was given in first line, the time that has
elapsed since first-line treatment, and co-morbidities.
For treatment in third line, only erlotinib has been
registered for the treatment of patients with PS 0–3 who
progress after second line and who are EGFR TKI naive. This
approach is based on one randomized trial where erlotinib
was compared with placebo in previously treated patients.
This trial included patients who had received one or two
prior regimens and who were not eligible for further
cytotoxic treatment. Erlotinib seems to be as beneficial in
third line as in second line [70].
A retrospective study in third-line NSCLC of 700 patients
found that survival and response rates decreased with each
subsequent regimen [74]. These patients should be offered
supportive care in addition to inclusion in clinical trials.
Recommendation 2: in second-line, chemotherapy or an
EGFR TKI can be offered to patients. In third line, an EGFR
TKI may be considered when patients have not received
EGFR TKIs previously. Patients in good general condition in
third or subsequent lines should be entered in clinical
studies.
Strength of recommendation: B
Level of evidence: II
3. Should patients with symptomatic brain
metastases be considered for treatment with EGFR
TKIs?
During the course of the disease 20%–30% of patients will have
brain metastases. After initial treatment with steroids,
anticonvulsive therapy and/or radiation, patients who are stable
might benefit from treatment with EGFR TKIs, albeit
controversial when the mutation status is unknown. Only one
single-center, single-arm study has reported response in 6 of 14
Japanese patients with brain metastases [75].
Recommendation 3: patients with symptomatic brain
metastases may be considered for treatment with an EGFR TKI.
Strength of recommendation: B
Level of evidence: V
4. Is age alone an exclusion criterion for
withholding treatment in second or third-line?
One recent retrospective analysis of 461 patients aged <70
versus >70 years showed no differences in median PFS (P =
0.08) and less nonsignificant toxicity in the nonelderly group
for all different treatments [76].
In the study comparing pemetrexed versus docetaxel in
second line, a subset analysis in the elderly population was
carried out. There was no statistically significant difference in
survival for patients >70 years of age (7.7 versus 8.0 months)
between the two treatment arms [77]. Elderly patients had
longer OS in the pemetrexed arm, but this was not statistically
significant.
Recommendation 4: age alone is not considered to be an
exclusion criterion for second- or third-line therapy.
Strength of recommendation: A
Level of evidence: III
5. Is second-line therapy indicated in patients with
progressive disease during first-line
chemotherapy?
Docetaxel [72], erlotinib [70], gefitinib (harboring an EGFR
mutation) [78], or pemetrexed [71] is considered acceptable as
second-line therapy for patients with NSCLC and good PS who
progressed during first-line therapy.
Recommendation 5: different drugs have been registered for
the treatment of patients who progress during first-line therapy.
Strength of recommendation: B
Level of evidence: I
6. Are there any selection criteria for the choice of
treatment in second or third-line NSCLC with
regard to histology?
Recommendation 6.1: for nonsquamous tumors, data support
the use of pemetrexed or EGFR TKIs.
Strength of recommendation: B
Level of evidence: II
Recommendation 6.2: for squamous tumors, data support the
use of docetaxel or EGFR TKIs.
Strength of recommendation: B
Level of evidence: II
7. Are there any selection criteria for the choice of
treatment in second- or third-line NSCLC with
regard to EGFR mutation status?
Recommendation 7.1: in the presence of EGFR sensitizing
mutations, the use of an EGFR TKI is recommended if not
received previously.
Strength of recommendation: B
Level of evidence: II
There are no convincing data to support the use of
chemotherapy or an EGFR TKI in patients with PS 3 or 4.
However, patients with activating EGFR mutations might
benefit from EGFR TKIs. In daily practice, there are many
patients in whom only supportive treatment is recommended.
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Recommendation 7.2: second- or third-line therapy with an
EGFR TKI might be considered even in patients with PS 3-4
harboring an activating EGFR mutation.
Strength of recommendation: C
Level of evidence: V
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